Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 3 3Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 10Neoplasm Metastasis 3Neoplasms 2Glioma 2Skin Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurofibroma, Plexiform 1Neuroblastoma 1Melanoma, Cutaneous Malignant 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × dabrafenib × Clear all
NCT01750918 2021-10-29

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Novartis

Phase 1/2 Completed
166 enrolled 46 charts
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Novartis

Phase 1/2 Completed
139 enrolled 42 charts 1 FDA
CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡